Omeros' Ophthalmology Product OMS302 Successful in Second Phase 3 Clinical Trial
That figure is what I feel they will need until the drug is bringing in revenue. they have roughly 40 million, that will get them through most of next year to approval. But you don't want a weak balance sheet. Depending on how fast the OMS302 brings in cash, they will have to raise another 60+ million, to fund 2014 and launch. So, 150 is larger side, but counting what they have now, they will need at least another 60 million.